Chronic GVHD, an autoimmune disease that follows allogeneic hematopoietic-cell
transplantation, is characterized by infections and debilitating tissue injury leading to …

Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Naive T cells have long been regarded as a developmentally synchronized and fairly
homogeneous and quiescent cell population, the size of which depends on age, thymic …

Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment
of relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as front …

With the increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor–
mobilized peripheral blood stem cell donor grafts and successful treatment of older …

Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly
tested in patients with advanced lymphoma. Following treatment, many of those patients are …

The adaptive immune system has the enormous challenge to protect the host through the
generation and differentiation of pathogen‐specific short‐lived effector T cells while in …

Hematopoietic stem/progenitor cells (HSPCs) are capable of supporting the lifelong
production of blood cells exerting a wide spectrum of functions. Lentiviral vector HSPC gene …

Chronic graft-versus-host disease (GVHD) can be associated with significant morbidity, in
part because of nonreversible fibrosis, which impacts physical functioning (eye, skin, lung …

Administration of posttransplant cyclophosphamide (PTCy) has significantly expanded the
number of patients undergoing HLA-haploidentical hematopoietic cell transplantation (haplo …